Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST-NMOSD: Rituximab vs Other Therapies in NMOSD
NCT07010302Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of rituximab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Massachusetts General Hospital. Started Sep 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07010302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010302.